Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Todd Rambasek

Allergy & Immunology Sandusky, OH Medical Doctor

NPI 1093814220 CMS profile 186208

2800 Hayes Ave Bldg C, Sandusky, OH 44870

Open in the dashboard

General payments

$52,637

367 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,194 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Todd Rambasek of Sandusky, OH is reported in the CMS Open Payments database as having received $52,637 across 367 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $15,194 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,100 88
2024 General $5,973 56
2023 General $13,318 65
2022 General $15,992 73
2021 General $591 36
2020 General $2,219 29
2019 General $445 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Todd Rambasek
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Todd Rambasek were reported at $14,100. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Todd Rambasek Allergy & Immunology median Middle half National median
2019 $445 $594 $163–$1,512 $163
2020 $2,219 $426 $106–$1,233 $114
2021 $591 $638 $157–$1,708 $132
2022 $15,992 $790 $205–$1,961 $149
2023 $13,318 $852 $220–$2,147 $160
2024 $5,973 $865 $203–$2,267 $164
2025 $14,100 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $35,964 99 payments
  2. Amgen Inc. $10,960 50 payments
  3. Genentech USA, Inc. $2,107 17 payments
  4. GlaxoSmithKline, LLC. $996 76 payments
  5. CSL Behring $400 15 payments
  6. Regeneron Healthcare Solutions, Inc. $354 19 payments
  7. OptiNose US, Inc. $291 16 payments
  8. Genzyme Corporation $258 12 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $212 9 payments
  10. Pfizer Inc. $175 10 payments
  11. Other $920 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,500 23 payments
  2. Food and Beverage $8,029 332 payments
  3. Consulting Fee $1,725 1 payment
  4. Travel and Lodging $216 7 payments
  5. Education $166 4 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE Respiratory $34,373 40 payments
  2. TEZSPIRE Inflammation $10,944 49 payments
  3. Xolair $2,107 17 payments
  4. NUCALA $747 63 payments
  5. DUPIXENT Immunology $523 22 payments
  6. AIRSUPRA $440 13 payments
  7. FASENRA Respiratory $387 17 payments
  8. FASENRA Respiratory $317 12 payments
  9. Xhance $291 16 payments
  10. DUPIXENT Inflammation And Immunology $254 14 payments
  11. Other $2,331 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,354

Median for Allergy/ Immunology: 449

Drug cost

$1,292,509

Median for Allergy/ Immunology: $169,700

Branded share of claims

35.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 13 $325,955
Dupixent Syringe Dupilumab Brand 53 $202,616
Dupixent Pen Dupilumab Brand 43 $190,624
Xolair Omalizumab Brand 58 $165,451
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 101 $85,728
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 18 $67,233
Breo Ellipta Fluticasone/Vilanterol Brand 91 $62,273
Spiriva Respimat Tiotropium Bromide Brand 60 $38,104
Dulera Mometasone/Formoterol Brand 28 $15,193
Arnuity Ellipta Fluticasone Furoate Brand 46 $14,836

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$695,182

Of which drugs: $615,231

Medicare patients

338

Average age 72

Services billed

32,818

222 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 54%
Diabetes 26%
Chronic kidney disease 22%
COPD 22%
Ischemic heart disease 21%
Depression 20%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 16 10,380 $293,178

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $4,791
  • Amgen Inc. $286
$5,076 — —
XOLAIR
  • Genentech USA, Inc. $175
  • Novartis Pharmaceuticals Corporation $57
$232 58 10,380
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $101
  • GENZYME CORPORATION $45
$145 96 —
NUCALA
  • GlaxoSmithKline, LLC. $128
$128 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

367 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record